⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29191973 | 0.74 | AXL (0.36) | — | |
| SCHEMBL17802124 | 0.73 | — | — | |
| SCHEMBL658808 | 0.73 | ERN1 (0.34) | — | |
| SCHEMBL2374543 | 0.73 | — | — | |
| SCHEMBL526476 | 0.72 | — | — | |
| SCHEMBL1938836 | 0.72 | — | — | |
| SCHEMBL1477717 | 0.72 | — | — | |
| SCHEMBL152386 | 0.72 | — | — | |
| SCHEMBL31470362 | 0.67 | — | — | |
| SCHEMBL7350671 | 0.65 | DRD4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608808-A1 | SOMATOSTATIN RECEPTOR 2 AGONISTS AND USES THEREOF | Basecamp Bio Inc. (KY) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024182778-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024089668-A1 | SOMATOSTATIN RECEPTOR 2 AGONISTS AND USES THEREOF | BASECAMP BIO INC. (KY) | 2024-05-02 | — | — | WO | disclosed |
| EP-3087155-A1 | CONTROL OF SUSTAINED CASING PRESSURE IN WELLBORE ANNULI | Albemarle Corporation (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20160289527-A1 | CONTROL OF SUSTAINED CASING PRESSURE IN WELLBORE ANNULI | ALBEMARLE CORP (US) | 2016-10-06 | — | — | US | disclosed |
| EP-2598481-B1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2598481-B1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015100004-A1 | CONTROL OF SUSTAINED CASING PRESSURE IN WELLBORE ANNULI | ALBEMARLE CORPORATION (US) | 2015-07-02 | — | — | WO | disclosed |
| US-8916553-B2 | Sulfonamide compounds useful as CYP17 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916553-B2 | Sulfonamide compounds useful as CYP17 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916553-B2 | Sulfonamide compounds useful as CYP17 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
| CN-102898359-B | Synthesis of 3, 5-dibromo-4-iodopyridine | UNIV XIHUA | 2014-03-26 | — | — | CN | disclosed |
| EP-2598481-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-06-05 | — | — | EP | disclosed |
| CN-102898359-A | Synthesis of 3, 5-dibromo-4-iodopyridine | UNIV XIHUA | 2013-01-30 | — | — | CN | disclosed |
| WO-2012015723-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015723-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |